Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma

P. Klener, E. Fronkova, D. Belada, K. Forsterova, R. Pytlik, M. Kalinova, M. Simkovic, D. Salek, H. Mocikova, V. Prochazka, P. Blahovcova, A. Janikova, J. Markova, A. Obr, A. Berkova, J. Kubinyi, M. Vaskova, E. Mejstrikova, V. Campr, R. Jaksa, R....

. 2018 ; 36 (1) : 110-115. [pub] 20171030

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18010289

Grantová podpora
NV17-28980A MZ0 CEP - Centrální evidence projektů

Implementation of cytarabine into induction therapy became standard of care for younger patients with mantle cell lymphoma (MCL). On the basis of its beneficial impact, many centers incorporated cytarabine at lower doses also into first-line treatments of elderly patients. We conducted a multicenter observational study that prospectively analyzed safety and efficacy of alternating 3 + 3 cycles of R-CHOP and R-cytarabine for newly diagnosed transplant-ineligible MCL patients. A total of 73 patients were enrolled with median age 70 years. Most patients had intermediate (39.7%) and high-risk (50.7%) disease according to MCL international prognostic index. Rituximab maintenance was initiated in 58 patients. Overall response rate reached 89% by positron emission tomography-computed tomography, including 75.3% complete remissions. Two patients (2.7%) did not complete the induction therapy because of toxicity. Three patients (4.1%) were considered nonresponders, which led to therapy change before completion of induction. Estimated progression-free survival and overall survival were 51.3% and 68.6% at 4 years, respectively. Mantle cell lymphoma international prognostic index, bulky disease (≥ 5 cm), and achievement of positron emission tomography-negativity independently correlated with progression-free survival. Grade 3 to 4 hematologic and nonhematologic toxicity was documented in 48% and 20.5% patients, respectively. Alternation of R-CHOP and R-cytarabine represents feasible and very effective regimen for elderly/comorbid MCL patients. This study was registered at GovTrial (clinicaltrials.gov) NCT03054883.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010289
003      
CZ-PrNML
005      
20241204100259.0
007      
ta
008      
180404s2018 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/hon.2483 $2 doi
035    __
$a (PubMed)29083050
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Klener, Pavel $u First Medical Department, Charles University General Hospital in Prague, Prague, Czech Republic. Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
245    10
$a Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma / $c P. Klener, E. Fronkova, D. Belada, K. Forsterova, R. Pytlik, M. Kalinova, M. Simkovic, D. Salek, H. Mocikova, V. Prochazka, P. Blahovcova, A. Janikova, J. Markova, A. Obr, A. Berkova, J. Kubinyi, M. Vaskova, E. Mejstrikova, V. Campr, R. Jaksa, R. Kodet, K. Michalova, J. Trka, M. Trneny,
520    9_
$a Implementation of cytarabine into induction therapy became standard of care for younger patients with mantle cell lymphoma (MCL). On the basis of its beneficial impact, many centers incorporated cytarabine at lower doses also into first-line treatments of elderly patients. We conducted a multicenter observational study that prospectively analyzed safety and efficacy of alternating 3 + 3 cycles of R-CHOP and R-cytarabine for newly diagnosed transplant-ineligible MCL patients. A total of 73 patients were enrolled with median age 70 years. Most patients had intermediate (39.7%) and high-risk (50.7%) disease according to MCL international prognostic index. Rituximab maintenance was initiated in 58 patients. Overall response rate reached 89% by positron emission tomography-computed tomography, including 75.3% complete remissions. Two patients (2.7%) did not complete the induction therapy because of toxicity. Three patients (4.1%) were considered nonresponders, which led to therapy change before completion of induction. Estimated progression-free survival and overall survival were 51.3% and 68.6% at 4 years, respectively. Mantle cell lymphoma international prognostic index, bulky disease (≥ 5 cm), and achievement of positron emission tomography-negativity independently correlated with progression-free survival. Grade 3 to 4 hematologic and nonhematologic toxicity was documented in 48% and 20.5% patients, respectively. Alternation of R-CHOP and R-cytarabine represents feasible and very effective regimen for elderly/comorbid MCL patients. This study was registered at GovTrial (clinicaltrials.gov) NCT03054883.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a myší monoklonální protilátky $x farmakologie $x terapeutické užití $7 D058846
650    _2
$a protokoly protinádorové kombinované chemoterapie $x farmakologie $x terapeutické užití $7 D000971
650    _2
$a cyklofosfamid $x farmakologie $x terapeutické užití $7 D003520
650    _2
$a cytarabin $x farmakologie $x terapeutické užití $7 D003561
650    _2
$a doxorubicin $x farmakologie $x terapeutické užití $7 D004317
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lymfom z plášťových buněk $x farmakoterapie $x patologie $7 D020522
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prednison $x farmakologie $x terapeutické užití $7 D011241
650    _2
$a vinkristin $x farmakologie $x terapeutické užití $7 D014750
655    _2
$a časopisecké články $7 D016428
700    1_
$a Fronkova, Eva $u CLIP, Deparment of Pediatric Hematology/Oncology, Second Faculty of Medicine and University Hospital in Motol, Prague, Czech Republic.
700    1_
$a Belada, David $u Fourth Department of Internal Medicine-Hematology, Charles University Hospital in Hradec Kralove and Faculty of Medicine in Hradec Kralove, Hradec Králové, Czech Republic.
700    1_
$a Forsterova, Kristina $u First Medical Department, Charles University General Hospital in Prague, Prague, Czech Republic.
700    1_
$a Pytlik, Robert $u First Medical Department, Charles University General Hospital in Prague, Prague, Czech Republic.
700    1_
$a Kalinova, Marketa $u Department of Pathology and Molecular Medicine, Charles University Hospital in Motol, Prague, and Second Faculty of Medicine, Prague, Czech Republic.
700    1_
$a Simkovic, Martin $u Fourth Department of Internal Medicine-Hematology, Charles University Hospital in Hradec Kralove and Faculty of Medicine in Hradec Kralove, Hradec Králové, Czech Republic.
700    1_
$a Salek, David $u Department of Hematology and Oncology, Masaryk University Hospital in Brno, Brno, Czech Republic.
700    1_
$a Mocikova, Heidi $u Department of Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Prochazka, Vit $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Blahovcova, Petra $u First Medical Department, Charles University General Hospital in Prague, Prague, Czech Republic.
700    1_
$a Janikova, Andrea $u Department of Hematology and Oncology, Masaryk University Hospital in Brno, Brno, Czech Republic.
700    1_
$a Markova, Jana $u Department of Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Obr, Ales $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Berková, Adéla $u Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University, Prague, Czech Republic. $7 xx0325890
700    1_
$a Kubinyi, Jozef $u Institute of Nuclear Medicine, Charles University General Hospital in Prague, Prague, Czech Republic.
700    1_
$a Vaskova, Martina $u CLIP, Deparment of Pediatric Hematology/Oncology, Second Faculty of Medicine and University Hospital in Motol, Prague, Czech Republic.
700    1_
$a Mejstrikova, Ester $u CLIP, Deparment of Pediatric Hematology/Oncology, Second Faculty of Medicine and University Hospital in Motol, Prague, Czech Republic.
700    1_
$a Campr, Vit $u Department of Pathology and Molecular Medicine, Charles University Hospital in Motol, Prague, and Second Faculty of Medicine, Prague, Czech Republic.
700    1_
$a Jaksa, Radek $u Institute of Pathology, Charles University General Hospital Prague, Prague, Czech Republic.
700    1_
$a Kodet, Roman $u Department of Pathology and Molecular Medicine, Charles University Hospital in Motol, Prague, and Second Faculty of Medicine, Prague, Czech Republic.
700    1_
$a Michalova, Kyra $u Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Trka, Jan $u CLIP, Deparment of Pediatric Hematology/Oncology, Second Faculty of Medicine and University Hospital in Motol, Prague, Czech Republic.
700    1_
$a Trneny, Marek $u First Medical Department, Charles University General Hospital in Prague, Prague, Czech Republic.
773    0_
$w MED00002019 $t Hematological oncology $x 0278-0232 $g Roč. 36, č. 1 (2018), s. 110-115
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29083050 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20241204100254 $b ABA008
999    __
$a ok $b bmc $g 1287774 $s 1007101
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 36 $c 1 $d 110-115 $e 20171030 $i 0278-0232 $m Hematological oncology $n Hematol Oncol $x MED00002019
GRA    __
$a NV17-28980A $p MZ0
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace